The FDA approved LEQEMBI IQLIK (lecanemab-irmb), a weekly under-the-skin injection, as a starting dose for early Alzheimer's disease — meaning people with mild cognitive impairment or mild dementia from Alzheimer's can now begin treatment with an autoinjector instead of months of IV infusions first. Eisai announced the approval on July 13, 2026, and the device reached U.S.
patients through specialty pharmacies on August 24, 2026. The practical answer for most readers is narrower than "at home." The first two doses must be given under a health care provider's supervision after device training, brain MRIs continue on a fixed schedule, and Medicare coverage still depends on your prescriber participating in an approved registry. Below is what each of those conditions means before you ask for a prescription.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Official resources:
- Explore the official data from FDA — Use this primary source to review the underlying data.
- Check eligibility on CMS’s official study page — Use this page to check the study’s participation requirements.
Table of Contents
- What the approval actually changed
- The approval rested on exposure data, not a new trial
- Why "at-home" still begins in the clinic
- The boxed warning and who carries the most risk
- Coverage, cost, and the registry requirement most families miss
- Where to start the conversation
- Frequently Asked Questions
What the approval actually changed
Before July 2026, lecanemab treatment started in an infusion chair. The subcutaneous autoinjector existed, but only as a maintenance option after a patient had already been on intravenous therapy. According to Eisai's announcement of the FDA approval, the agency cleared IQLIK as an initiation dose for early Alzheimer's — mild cognitive impairment or mild dementia due to Alzheimer's, with amyloid pathology confirmed by testing. The starting regimen is 500 mg once weekly, given as two consecutive 250 mg injections.
Eisai reports each injection takes about 15 seconds and goes into the abdomen, thigh, or the back of the upper arm. After 18 months of treatment — by IV or injection — the dose steps down to 360 mg once weekly for maintenance. Eligibility has not loosened. "Confirmed amyloid pathology" means a PET scan, spinal fluid test, or an approved blood test showing amyloid plaque in the brain. A memory complaint, or even a dementia diagnosis without that confirmation, does not qualify someone for this drug by any route.
The approval rested on exposure data, not a new trial
Eisai did not run a second large efficacy study for the injection. The company reports that sub-studies inside the long-term extension of the Phase 3 Clarity AD trial showed once-weekly subcutaneous dosing reached drug exposure equivalent to the IV form. The FDA accepted that bridging evidence.
The clinical benefit figure, then, comes from the original IV trial: over 18 months, lecanemab slowed decline by 27% compared with placebo on the CDR-SB scale, a measure of memory, judgment, and daily function scored by a clinician. That is a slowing, not a stopping or a reversal. A family deciding whether to start should read 27% as a modest shift in the rate of change over a year and a half, not a restoration of lost function.
Why "at-home" still begins in the clinic
The label does not hand a new patient a device on day one. Patients or care partners may inject at home only after completing at least two consecutive subcutaneous doses under provider supervision, with device training beforehand — a sequence reported by Neurology Advisor in its coverage of the subcutaneous initiation approval. Imaging is the harder constraint.
The FDA prescribing information calls for a baseline brain MRI plus follow-up MRIs after 1, 2, 3, and 6 months of dosing, with heightened clinical vigilance through roughly the first 14 weeks. That is five scans in the first half-year and regular contact with a specialist. Injecting at home removes the infusion appointment; it does not remove the monitoring schedule built around it. Practically, that means a household should plan for:.
- Device training plus two supervised injection visits before any home dosing
- Four follow-up MRIs in the first six months, on top of the baseline scan
- A specialist reachable quickly during the first 14 weeks
- Weekly dosing with no gaps — this is a once-a-week drug indefinitely, not a course
The boxed warning and who carries the most risk
The label keeps its boxed warning for amyloid-related imaging abnormalities, or ARIA — brain swelling (ARIA-E) and small brain bleeds (ARIA-H) that show up on MRI. The FDA label states ARIA can be fatal. ARIA-E occurred in 13% of patients on lecanemab versus 2% on placebo. Risk is not evenly spread.
ARIA was highest in people who carry two copies of the ApoE ε4 gene variant — about 45% — and the label advises genotype testing before treatment. A homozygous ε4 result does not automatically rule out therapy, but it changes the math enough that it should be known before the first dose, not after. Symptoms that warrant an immediate call include new or worsening headache, confusion, dizziness, vision changes, nausea, or seizure. Because the drug is now injected at home by a family member rather than infused under observation, the person doing the injecting is also the person most likely to notice these first.
Coverage, cost, and the registry requirement most families miss
Medicare coverage of anti-amyloid antibodies still runs through CMS national coverage determination 200.3, which covers this class only under Coverage with Evidence Development. Use outside a qualifying trial or a CMS-approved registry is nationally non-covered. Your prescriber's registry participation gates access — and the injection route does not change that. Ask the clinic directly whether it submits to a CMS-approved registry before you schedule anything. On price, Eisai's U.S.
price list effective October 5, 2026 lists $385 per 360 mg/1.8 mL autoinjector, or $4,620 for a 12-unit case. The autoinjector launched in 2025 at a $375 wholesale acquisition cost, which Eisai equated to roughly $19,500 a year. The dispensing channel matters for what a patient actually pays. Because the autoinjector goes through specialty pharmacy rather than an infusion suite, cost exposure can land under the Part D drug benefit instead of Part B. CMS set the 2026 annual out-of-pocket threshold at $2,100, up from $2,000, with no cost-sharing above it — a hard annual ceiling that the Part B coinsurance structure for infusions does not offer.
Where to start the conversation
Eisai and Biogen dispense the initiation autoinjector through the LEQEMBI Specialty Pharmacy Network, which includes CareMed and Walgreens Specialty. Per the companies' availability announcement, that network handles insurance navigation, delivery, and device-use education, and ships a Welcome Kit with a demonstration device and an Instructions-for-Use video.
Bring four questions to the neurologist or memory clinic: Has amyloid been confirmed, and how? What is my ApoE ε4 genotype? Does this practice report to a CMS-approved registry? And who in my household will be trained to inject, and are they willing? A care partner who is uncomfortable with needles is a real reason to stay on infusions, and clinics expect that answer. If a clinic cannot confirm registry participation, the injection is not a workaround. The same national coverage rule applies to the autoinjector and the IV bag alike.
Frequently Asked Questions
Can I switch from IV infusions to the autoinjector partway through treatment?
The 18-month clock counts either route. After 18 months of IV or subcutaneous treatment, the dose drops to 360 mg once weekly for maintenance, so time already spent on infusions counts toward that step-down.
Does a mild cognitive impairment diagnosis alone qualify me?
No. The approval covers mild cognitive impairment or mild dementia due to Alzheimer's disease with confirmed amyloid pathology. Amyloid has to be documented by testing before treatment starts.
How long does a single dose take?
The weekly 500 mg starting dose is two consecutive 250 mg injections, each taking about 15 seconds according to Eisai — into the abdomen, thigh, or back of the upper arm.
You Might Also Like
- At-Home Leqembi vs IV Infusions After the 2026 FDA Decision: Access, Coverage, and Training Questions for People With Mild Cognitive Impairment
- FDA’s 2026 At-Home Leqembi IQLIK Starting Dose: Benefits, Limits, and Evidence Gaps for People With Mild Cognitive Impairment
- Subjective Cognitive Decline Data for Public Health Action in 2026: Access and Equity Questions for Adults in Midlife
